What impact can molnupiravir have on the treatment of SARS-CoV-2 infection?

Expert Opin Pharmacother. 2022 Jun;23(8):865-868. doi: 10.1080/14656566.2022.2057795. Epub 2022 Mar 28.

Fatima Kayali¹, Marco Shiu Tsun Leung^{2

3}, Wilson Wong⁴, Kara Pittendrigh Morgan^{5

6}, Amer Harky⁷

¹ UCLan Medical School, University of Central Lancashire, Preston, UK.
² The Hillingdon Hospitals Foundation Trust, Uxbridge, UK.
³ Imperial College Healthcare NHS Trust, London, UK.
⁴ Ealing Hospital, London North West University Healthcare NHS Trust, Southall, UK.
⁵ Department of Cardiology, Manchester Royal Infirmary, Manchester, UK.
⁶ Division of Pharmacy & Optometry, School of Health Sciences, Faculty of Biology, Medicine & Health, The University of Manchester, Manchester, UK.
⁷ Department of Cardiothoracic Surgery, Liverpool Heart and Chest Hospital, Liverpool, UK.

No abstract available

Keywords: Antivirals; COVID-19; SARS-CoV-2; coronavirus; molnupiravir; pharmacotherapy.

Publication types

This manuscript was not funded.